ICON PLC
F:IJF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
ICON PLC (IJF) under the Base Case is 147.91 EUR per share.
Compared with the current market price of 169.5 EUR, the stock appears
Overvalued by 13% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What ICON Does
ICON PLC is a contract research organization that helps drugmakers and medical device companies run clinical trials. It plans and manages studies, recruits patients, collects and analyzes trial data, and helps customers navigate the regulatory steps needed to test new treatments. The company also offers lab and data services that support drug development from early testing through late-stage trials.
- Headquarters
- Ireland IE
- Employees
- 40 100
- IPO date
- May 15, 1998
ICON has no economic moat
Sponsors can choose among several research providers for new studies, and ICON’s global reach does not prevent rivals from competing for that work. Its experience and range of services are useful, but they do not appear to lock customers in or give the company a lasting ability to charge more than alternatives.
Read the full moat analysisBalance Sheet
Recent Events
Latest Earnings Call
ICON narrowed its 2026 outlook as higher pass-throughs lifted revenue expectations, while management pointed to early direct-fee recovery and framed 2027 growth as plausible—not guidance.
Open the earnings call- EPS
- $2.46
- Expected
- $2.40
- Surprise
- +2.5%
- Stock, day of the call
- +17.0%
ICON insiders are selling more than usual
Insiders sell for many reasons, such as taxes or planned sales; purchases are rarer.
Past 12 months
Continue IJF Research
Decided on ICON? Get an email when IJF reaches the price you’d buy at. Free with an account.
Other ICON listings
What is the Intrinsic Value of one IJF stock?
The intrinsic value for
ICON PLC (IJF) under the Base Case is 147.91 EUR.
Is IJF stock undervalued or overvalued?
Compared with the current market price of 169.5 EUR, the stock appears Overvalued by 13% .